Please check your internet connection and try again.
# Isoxsuprine Hydrochloride
## Overview
Isoxsuprine hydrochloride is a vasodilator agent, historically used to improve blood flow. Its efficacy in peripheral vascular disease and cerebrovascular insufficiency is not well-established by robust clinical trials.
## Primary Indications
* Historically used for peripheral vascular disease and cerebrovascular insufficiency. Its current use for these indications is limited due to lack of strong evidence.
## Adult Dosing
* **Peripheral Vascular Disease:** Typically 10-20 mg orally every 3-4 times daily.
* **Cerebrovascular Insufficiency:** Doses may vary; consult prescribing information or local protocol.
## Pediatric Dosing
* No established pediatric dosing.
## Dose Adjustments
* No specific dose adjustments are typically recommended for renal or hepatic impairment, but caution is advised.
## Contraindications
* Patients who have had a recent myocardial infarction.
* Hypersensitivity to isoxsuprine.
* Caution in patients with severe atherosclerosis or coronary artery disease.
## Adverse Effects
* **Common:** Hypotension, tachycardia, dizziness, flushing, nausea, vomiting, abdominal distress.
* **Less Common:** Rash, drowsiness, weakness, nervousness.
## Key Drug Interactions
* **Antihypertensives:** May potentiate hypotensive effects.
* **Epinephrine:** May cause paradoxical decrease in blood pressure and decrease heart rate.
## Monitoring
* Blood pressure and heart rate.
* Symptoms of peripheral vascular disease or cerebrovascular insufficiency.
## Clinical Pearls
* The evidence supporting the use of isoxsuprine for its primary indications is weak.
* Onset of action is typically within 30 minutes, with peak effects at 1-2 hours.
* Tachycardia and hypotension are dose-limiting adverse effects.
***
*Disclaimer: This information is intended for clinical professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and relevant guidelines before making treatment decisions.*
